Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform

Leerink initiated coverage of Atrium Therapeutics (RNA) with an Outperform rating and $25 price target calling the company “an interesting preclinical-stage opportunity in precision cardiology.” While the company’s programs may be higher risk given the lack of human cardiac data to date, the firm sees favorable risk/reward driven by “a clear, early catalyst path.” The firm expects an IND filing for ATR 1072 in PRKAG2 syndrome in the second half of 2026, followed by Phase 1 initiation and early proof-of-concept potentially as early as 2027, the analyst tells investors.